First Bank & Trust lifted its stake in shares of AstraZeneca plc (NYSE:AZN) by 19.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,597 shares of the company’s stock after purchasing an additional 9,004 shares during the period. AstraZeneca accounts for 1.5% of First Bank & Trust’s holdings, making the stock its 16th biggest position. First Bank & Trust’s holdings in AstraZeneca were worth $1,929,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in AZN. WFG Advisors LP raised its stake in shares of AstraZeneca by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $133,000. Quadrant Capital Group LLC raised its stake in shares of AstraZeneca by 18.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after purchasing an additional 846 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $184,000. Finally, FTB Advisors Inc. raised its stake in shares of AstraZeneca by 3.2% during the 2nd quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock worth $197,000 after purchasing an additional 200 shares in the last quarter. Institutional investors own 14.75% of the company’s stock.

AstraZeneca plc (AZN) traded down $0.05 during mid-day trading on Thursday, hitting $35.03. The company had a trading volume of 2,279,241 shares, compared to its average volume of 3,329,873. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. AstraZeneca plc has a 1-year low of $26.51 and a 1-year high of $35.92. The firm has a market cap of $86,850.00, a price-to-earnings ratio of 25.02, a PEG ratio of 3.42 and a beta of 0.76.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.55. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The firm had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the firm posted $1.32 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. research analysts predict that AstraZeneca plc will post 1.88 EPS for the current fiscal year.

A number of research analysts recently weighed in on AZN shares. Sanford C. Bernstein raised AstraZeneca from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $30.00 to $39.00 in a report on Friday, September 22nd. BNP Paribas raised AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Credit Suisse Group raised AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Cowen reissued a “hold” rating and set a $37.00 target price on shares of AstraZeneca in a report on Tuesday, October 17th. Finally, Citigroup raised AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and an average target price of $34.48.

COPYRIGHT VIOLATION WARNING: “First Bank & Trust Has $1.93 Million Stake in AstraZeneca plc (AZN)” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://theolympiareport.com/2018/01/18/first-bank-trust-has-1-93-million-stake-in-astrazeneca-plc-azn.html.

AstraZeneca Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.